RJRajamma Abburu Jayaramu

Rajamma Abburu Jayaramu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rajamma Abburu Jayaramu has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Rational design and characterisation of intranasal gel incorporating eletriptan HBr-loaded solid lipid nanoparticles for enhanced brain delivery in migraine

    by Shrikishan Budharam, Sateesha Shivally Boregowda, Reem Binsuwaidan, Mohd Adnan, Nawaf Alshammari, Fahad Almarshadi, Chandan Ravandur Shivanna, Rajamma Abburu Jayaramu

  • Eletriptan HBr-loaded solid lipid nanoparticle-integrated microneedles: a targeted and minimally invasive approach for migraine management

    by Ankith Nallapeta Amaranatha, Sateesha Shivally Boregowda, Shivanand Kalyanappa Mutta, Rajamma Abburu Jayaramu, Chandan Ravandur Shivanna, Durgashree Diwakar, Shrikishan B., Girija Easwaradas Kreedapathi

    INTRODUCTIONEletriptan hydrobromide (EHBr) is a potent and clinically reliable anti-migraine agent, exerting its therapeutic effect primarily through modulation of calcitonin gene-related peptide (...


  • In-situ Gel Systems for Periodontitis: Advances in Localized Drug Delivery and Regenerative Therapy

    by Afrasim Moin, Sateesha Shivally Boregowda, Ranjitha S, Gokul Chowdappa, Rajamma Abburu Jayaramu, Shivanand K

    Periodontitis is a chronic inflammatory condition initiated by pathogenic microbial biofilms and exacerbated by host immune responses, leading to progressive connective tissue and alveolar bone destruction and eventual tooth loss. Conventional therapies such as scaling and root planning, systemic antibiotics, and surgical interventions provide only short-term relief due to rapid drug clearance, limited penetration into deep periodontal pockets, and poor efficacy against structured biofilms. These limitations underscore the need for localized, sustained drug delivery systems capable of maintaining therapeutic concentrations at the target site. In-situ gel systems have emerged as innovative localized delivery platforms for periodontal therapy. Administered as liquids, they undergo sol-to-gel transitions in response to physiological stimuli such as temperature, pH, or ionic strength within the periodontal pocket, ensuring prolonged retention and improved therapeutic performance. Advances in polymer design, crosslinking chemistry, and fabrication methods including click reactions and supramolecular assembly have enhanced gel stability, responsiveness, and controlled release behaviour. Integration of nanotechnology, advanced biomaterials, three-dimensional bioprinting, and AI driven formulation strategies has further refined drug loading and delivery precision. Collectively, these innovations position smart in-situ gels as next generation systems for effective and sustained management of chronic periodontitis.


  • Decoding psoriasis: pathological mechanisms, evolving treatments, clinical investigations, and future perspectives

    by Afrasim Moin, Sateesha Shivally Boregowda, Gokul Chowdappa, Rajamma Abburu Jayaramu, Abubakar Mohamedtoom Awadalkarim

    1. Psoriasis represents a persistent, immune-mediated dermatological disorder characterized by inflammation and scaling plaques that result from abnormal keratinocyte proliferation. The global prev...


  • Development and evaluation of cationic surface-modified hydroxyapatite nanoparticles for enhanced membrane permeation

    by Rajamma Abburu Jayaramu, Sateesha Shivally Boregowda, Shivanand K., Shruthi Eshwar, Girija E.K, Vivekanand K., Muthu Devaraj

    This study aimed to develop positively charged, metronidazole-loaded hydroxyapatite (MZ-HP) nanoparticles with enhanced membrane interaction, permeation, and therapeutic efficacy through surface charge modulation using cetyltrimethylammonium bromide (CT). Mesoporous HP nanoparticles were synthesized from eggshell-derived calcium oxide and loaded with metronidazole, followed by CT coating (1-3.5 mM/g MZ-HP) via physisorption. Drug loading and CT adsorption were confirmed by FTIR and XRD, while SEM and TEM assessed morphology and coating induced structural changes. Particle size and zeta potential were measured using dynamic light scattering to evaluate surface charge modulation. Ex vivo porcine skin permeation studies assessed drug release and permeability. Cytocompatibility was evaluated using an MTT assay on L929 fibroblasts. MZ-HP nanoparticles were successfully formulated with a maximum loading efficiency of 87.2% at an MZ:HP ratio of 0.83 M:1 M, showing a strong positive correlation between drug to carrier ratio and loading efficiency (r = 0.90, P = 0.039). CT coating shifted the surface charge from -28.3 ± 5.12 mV (HP) to -20.5 ± 4.1 mV (MZ-HP) and further to +21.9 ± 3.3 mV (CT-MZ-HP), confirming effective charge reversal. Permeability flux increased from 1.285 to 1.582 mg/h·cm², indicating enhanced interaction with negatively charged biological membranes. Cytotoxicity studies demonstrated improved fibroblast tolerance for CT-MZ-HP (IC₅。 = 184.9 ± 3.12 µg/mL) compared to CT, inferring its short-term dermal safety and enhanced cytocompatibility. CT coated MZ-HP nanoparticles provide an effective charge-modulated nanocarrier system with enhanced trans-barrier transport, membrane interaction, intracellular access, and cytocompatibility, supporting their potential as next-generation antimicrobial delivery platforms.


  • Open Access

    Piperine-loaded solid lipid nanoparticles: a promising nano-phytomedicine for the treatment of non-alcoholic fatty liver disease

    by Afrasim Moin, Shwetha Ram, Sateesha Shivally Boregowda, Talib Hussain, Amr Selim Abu Lila, Rajamma Abburu Jayaramu, Syed Mohd Danish Rizvi, Sirajudheen Anwar, Kalegowda Chandan

    Introduction: Piperine (PIP), the active alkaloid found in black pepper ( Piper nigrum ), has gained attention for its potential therapeutic role in managing non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, lipid-lowering, antioxidant, and insulin-sensitising properties. Nevertheless, PIP’s poor solubility limits its absorption in the gastrointestinal tract, thereby, compromising its systemic bioavailability. Consequently, the objective of this research has been to formulate piperine-loaded solid lipid nanoparticles (PIP- SLNs) so as to increase its oral bioavailability and prolong its hepatic circulation time. Methods: Herein, PIP-SLNs were prepared by the hot homogenization method. The fabricated PIP-SLNs were characterized for size, zeta potential, surface morphology, entrapment efficiency and in vitro release performance. The impact of the optimized formula (F6) on key parameters associated with NAFLD, such as oral glucose tolerance (OGTT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol (TC), triglyceride (TG) levels, and liver weight, was evaluated using a hyperlipidaemic Swiss albino mice model. Additionally, liver histopathology was examined pre- and post-treatment to assess the efficacy of PIP-SLNs in mitigating hyperlipidaemia. Results and discussion: Particle size, zeta potential, and drug entrapment efficiency of the optimized formula (F6) was found to be 191.2 ± 27.9 nm, - 20 ± 1.3 mV, 72.3% ± 2.8, respectively. Morphologically, the PIP-SLNs were found to be spherical. The optimized formulation (F6) exhibited sustained release up to 70% at 48 h, fitting the Higuchi model (R 2 = 0.976) indicative of diffusion-driven release, with a Korsmeyer‐Peppas exponent (n = 0.63), further confirming anomalous diffusion-relaxation transport. Most importantly, the NAFLD study demonstrated a significant (p < 0.05) drop in blood glucose levels, serum markers (AST and ALT, p < 0.001), total cholesterol and triglycerides (p < 0.05), and also liver weight (p < 0.028), which was far superior to those elicited by plain PIP suspension. These findings reiterate the potential of solid lipid nanoparticles in increasing the bioavailability and thereby its hepatic circulation of PIP, which in turn, significantly enhanced its hepatoprotective effect in NAFLD.


  • Open Access

    Solid-State Characterization of Fluconazole Polymorphs: Temperature and Time-Triggered Analysis

    by Afrasim Moin, Vrss Prashanth Pedamallu, Sateesha Shivally Boregowda, Rajamma Abbur Jayaramu, Sathvik Kudkuli, Amr Selim Abu Lila

    BackgroundAn antifungal drug, fluconazole, was selected as a model drug in this study to comprehend the effect of temperature and moisture on polymorphic transformation.Materials and MethodsThree polymorphs of fluconazole namely, Polymorph I, Polymorph II and Polymorph III, were prepared by the single solvent crystallization method using acetone, methanol, and isopropyl alcohol. The polymorphs were characterized by FTIR, DSC, XRPD, and equilibrium solubility studies to illustrate the solid-state transformation. The effects of moisture {65 ± 5% Relative Humidity (RH) at 28 ± 2°C}, and the temperature, ranging from 30 to 100°C, on the polymorphic transformation was investigated.Results and DiscussionThe three polymorphs showed an endotherm at 140.19°C, 142.53°C, and 142.04°C, respectively. The fluconazole polymorph I and polymorph II showed polymorphic transformation at 80°C and on the 10th and 29th days, respectively, at 65 ± 5% RH/28 ± 2°C. On the other hand, the polymorph III, having a melting point of 120 ± 2°C, underwent polymorphic transformation at 90°C and on the 19th day at 65 ± 5% RH/28 ± 2°C. The impact of moisture on polymorphic transformation was evidenced by the remarkable shift of FTIR absorption peaks along with changes in their melting point.ConclusionIn summary, energetic steps involving heating of the drug and exposure to moisture will bring about polymorphic transformation in fluconazole, which result in changes in its solubility and, hence, it’s biological performance.


  • Chitosan–β-glycerophosphate thermogelling microneedles for transdermal contraceptive delivery of levonorgestrel

    by Chethan Kumar K. B., Sateesha S. B., Ankith N. A., Rajamma A. J., Durgashree Diwakar, Girija E. K., Likhitha C. N.

    This study presents the development of dissolving microneedles (LMNs) incorporating a chitosan-β-glycerophosphate thermogelling system for sustained transdermal delivery of levonorgestrel (LNG) as a contraceptive. Polyvinylpyrrolidone K90 and Dextran 40 were included to enhance mechanical strength and control drug release. LMNs fabricated using PDMS molds exhibited uniform, sharp structures as confirmed by SEM. FTIR and XRD analyses demonstrated chemical compatibility and physical stability of LNG within the matrix. The optimized LMNs showed significant mechanical strength (P < 0.05) and high insertion efficiency (F = 17.83, P = 3.03 × 10-8) across Parafilm® layers and fully dissolved within 30 minutes in porcine skin. Ex vivo studies revealed sustained LNG release (70.86 ± 0.42%) over 48 hours, outperforming a topical gel (42.33 ± 0.91%). Drug release followed first-order kinetics (R2 = 0.996) and non-Fickian diffusion (n = 0.79), indicating a combined diffusion-erosion mechanism. In vivo evaluation in Wistar rats showed significant contraceptive efficacy, with reduced implantation sites (0.5 ± 0.55) and uterine thickness (3.66 ± 0.51 mm; p < 0.0001), comparable to oral LNG. These results highlight LMNs as a promising, minimally invasive platform for long-acting transdermal contraception, offering improved bioavailability, patient compliance, and therapeutic effectiveness.


  • Cyanocobalamin-loaded dissolving microneedles for enhanced transdermal delivery: development, characterization, and pharmacokinetic evaluation

    by Mousam Bhowmik, Rajamma A. J., Sateesha S. B., Chandan R. S., Girija E. K., Punith M, Ebna Azizal Omar, Rajesh R

    This study demonstrates cyanocobalamin-loaded dissolving microneedles (CNBL-MNs) as a minimally invasive transdermal solution for managing cyanocobalamin (CNBL) deficiency, offering an alternative to intramuscular injections and oral supplements. The CNBL-MNs were developed using biodegradable, water-soluble polymers such as polyvinylpyrrolidone K25, Dextran K40, and chitosan to ensure controlled and gradual release of the CNBL. The formulation’s stability and integrity were assessed through FTIR and XRD analyses. SEM imaging revealed well-formed microneedles with a height of 800 μm, a 200 μm base diameter, and a 500 μm pitch. EDS confirmed the successful incorporation of CNBL in the microneedle array. The Parafilm® membrane insertion test revealed that the microneedles had strong mechanical properties and achieved 100% penetration efficiency. The microneedle array also demonstrated excellent (P > 0.05) flexibility and structural stability. Ex-vivo release studies showed that 88.51% of the CNBL was released over 48 h, following a first-order kinetic model. The n value of 0.51 for Korsmeyer-Peppas model indicate an anomalous transport mechanism, suggesting a combination of diffusion and erosion. The in-vivo pharmacokinetic evaluation in Wistar rats demonstrates that CNBL-MNs-2 exhibited a larger area under the curve (AUC₀–t) (61.57 ± 4.23 ng·h/mL) than the IP injection (37.04 ± 5.83 ng·h/mL), indicating significant (p > 0.05) increase in systemic availability and sustained release. The Cmax of CNBL-MNs-2 (6.10 ± 0.533 ng/mL) was comparable to that of the IP injection (6.20 ± 1.5 ng/mL), confirming efficient systemic absorption via the microneedle system. Additionally, Tmax was significantly (p > 0.05) prolonged with CNBL-MNs-2 (8 h) compared to the IP injection (2 h), suggesting a slower, more controlled CNBL release.


  • Design and formulation of fast-dissolving microneedles for the rapid transdermal delivery of lorazepam

    by Punith M., Rajamma A. J., Sateesha S. B., Durgashree Diwakar, Girija E. K., Chethan Kumar K. B., Ankith N. A., Mousam Bhowmik, Manjunatha P. M.

    This study investigates lorazepam-loaded dissolving microneedles (LMNs) as a fast-acting and minimally invasive treatment for status epilepticus. The LMNs were developed using a micro-moulding technique with an optimised combination of PVP K30, Dextran 40 and Pullulan. Their stability was confirmed through Fourier transform infra-red (FTIR) spectroscopy and X-ray diffraction (XRD) analysis. The Parafilm® membrane insertion test demonstrated 100% penetration efficiency, verifying their ability to effectively pierce the skin. Scanning electron microscopy (SEM) imaging revealed well-defined microneedles with precise dimensions (800 µm height, 200 µm base and 500 µm pitch). The LMNs rapidly dissolved in the subdermal layer of porcine skin. An ex vivo drug diffusion study showed that 3-5% of the encapsulated lorazepam was released within 30 min, with a cumulative release of 79.3% over 24 h. An acute dermal irritation study confirmed the biocompatibility and skin tolerance of the LMNs. Additionally, an in vivo anti-convulsant efficacy study in Albino Wistar rats subjected to maximal electroshock seizures demonstrated significant anticonvulsant effects (p < .05), confirming efficient systemic delivery of lorazepam. These findings highlight LMNs as a rapid-acting, non-invasive transdermal drug delivery system for managing status epilepticus, particularly in ambulatory care settings.